Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $2,480 | 3 | 61.7% |
| Honoraria | $1,170 | 1 | 29.1% |
| Food and Beverage | $303.36 | 4 | 7.5% |
| Travel and Lodging | $65.54 | 2 | 1.6% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $2,337 | 4 | $0 (2024) |
| Rigel Pharmaceuticals, Inc. | $1,383 | 4 | $0 (2023) |
| BeiGene, Ltd. | $280.00 | 1 | $0 (2024) |
| PFIZER INC. | $19.02 | 1 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,405 | 3 | ABBVIE INC. ($1,125) |
| 2023 | $2,528 | 5 | Rigel Pharmaceuticals, Inc. ($1,317) |
| 2022 | $19.02 | 1 | PFIZER INC. ($19.02) |
| 2020 | $66.17 | 1 | Rigel Pharmaceuticals, Inc. ($66.17) |
All Payment Transactions
10 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 03/22/2024 | BeiGene, Ltd. | BRUKINSA (Drug) | Consulting Fee | Cash or cash equivalent | $280.00 | General |
| Category: Oncology | ||||||
| 01/23/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $1,100.00 | General |
| 01/23/2024 | ABBVIE INC. | — | Travel and Lodging | In-kind items and services | $25.28 | General |
| 12/08/2023 | AbbVie Inc. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $111.60 | General |
| Category: ONCOLOGY | ||||||
| 03/13/2023 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Honoraria | Cash or cash equivalent | $1,170.00 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 03/13/2023 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Food and Beverage | Cash or cash equivalent | $106.57 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 03/13/2023 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Travel and Lodging | Cash or cash equivalent | $40.26 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 01/25/2023 | AbbVie Inc. | VENCLEXTA (Drug) | Consulting Fee | Cash or cash equivalent | $1,100.00 | General |
| Category: ONCOLOGY | ||||||
| 04/19/2022 | PFIZER INC. | VYNDAQEL (Drug) | Food and Beverage | In-kind items and services | $19.02 | General |
| Category: CARDIOVASCULAR | ||||||
| 08/13/2020 | Rigel Pharmaceuticals, Inc. | Tavalisse (Drug) | Food and Beverage | In-kind items and services | $66.17 | General |
| Category: Hematology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 125 | 343 | $141,107 | $28,794 |
All Medicare Procedures & Services
5 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 35 | 174 | $48,372 | $11,656 | 24.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 28 | 93 | $37,854 | $7,606 | 20.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 29 | 29 | $25,895 | $4,449 | 17.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 21 | 35 | $25,614 | $4,255 | 16.6% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2023 | 12 | 12 | $3,372 | $828.60 | 24.6% |
About Dr. Evan Chen, MD
Dr. Evan Chen, MD is a Medical Oncology healthcare provider based in Boston, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/10/2016. The National Provider Identifier (NPI) number assigned to this provider is 1679929574.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Evan Chen, MD has received a total of $4,019 in payments from pharmaceutical and medical device companies, with $1,405 received in 2024. These payments were reported across 10 transactions from 4 companies. The most common payment nature is "Consulting Fee" ($2,480).
As a Medicare-enrolled provider, Chen has provided services to 125 Medicare beneficiaries, totaling 343 services with total Medicare billing of $28,794. Data is available for 1 year (2023–2023), covering 5 distinct procedure/service records.
Practice Information
- Specialty Medical Oncology
- Location Boston, MA
- Active Since 05/10/2016
- Last Updated 03/06/2023
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1679929574
Products in Payments
- Rezlidhia (Drug) $1,317
- VENCLEXTA (Drug) $1,212
- BRUKINSA (Drug) $280.00
- Tavalisse (Drug) $66.17
- VYNDAQEL (Drug) $19.02
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Medical Oncology Doctors in Boston
Dr. George Demetri, Md, MD
Medical Oncology — Payments: $1.6M
Pasi Antero Janne, Md Phd, MD PHD
Medical Oncology — Payments: $1.1M
Dr. Praful Ravi, Mb Bchir, MB BCHIR
Medical Oncology — Payments: $921,658
Dr. Alicia Morgans, Md, MD
Medical Oncology — Payments: $755,277
Dr. Erica Mayer, Md Mph, MD MPH
Medical Oncology — Payments: $665,160
Dr. Joaquin Bellmunt Molins, M.d, M.D
Medical Oncology — Payments: $610,701